Eli Lilly (LLY) EBIT Margin (2009 - 2026)

Eli Lilly (LLY) has reported EBIT Margin for 18 consecutive years, with 47.98% the latest figure, recorded in Q1 2026.

• EBIT Margin for Q1 2026 came in at 47.98%, up 660.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 46.29% (up 787.0% YoY), and the FY2025 annual result was 44.82%, up 890.0% from the prior year.
• EBIT Margin was 47.98% for Q1 2026 at Eli Lilly, up from 46.15% in the prior quarter.
• Over five years, EBIT Margin peaked at 47.98% in Q1 2026 and troughed at 22.97% in Q1 2023.
• Average EBIT Margin over 5 years is 35.15%, with a median of 34.23% recorded in 2024.
• Year-over-year, EBIT Margin tumbled 993 bps in 2023 and surged 1150 bps in 2025.
• Over 5 years, EBIT Margin stood at 28.44% in 2022, then grew by 13 bps to 32.18% in 2023, then grew by 23 bps to 39.44% in 2024, then rose by 17 bps to 46.15% in 2025, then climbed by 4 bps to 47.98% in 2026.
• Per Business Quant data, the three most recent EBIT Margin figures were 47.98% in Q1 2026, 46.15% in Q4 2025, and 45.57% in Q3 2025.